Shuttle Pharmaceuticals (SHPH) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 13, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41488
Entity Registrant Name	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Entity Central Index Key	0001757499
Entity Tax Identification Number	82-5089826
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	401 Professional Drive
Entity Address, Address Line Two	Suite 260
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20879
City Area Code	(240)
Local Phone Number	403-4212
Title of 12(b) Security	Common Stock
Trading Symbol	SHPH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		15,999,125

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 3,885,997	$ 8,417,203
Prepaid expenses	170,104	161,148
Marketable securities	2,920,592
Accrued interest income	12,435
Other assets	6,480
Total Current Assets	6,995,608	8,578,351
Property and equipment, net	26,810	12,592
Other assets		6,480
Operating lease right-of-use asset	353,400	56,122
Total Assets	7,375,818	8,653,545
Current Liabilities
Convertible notes payable, net	462,825
Operating lease liability	61,034	62,823
Total Current Liabilities	810,437	975,676
Convertible notes payable non-current, net	134,382
Derivative liabilities	512,825
Operating lease liability non-current	308,425
Total Liabilities	1,766,069	975,676
Stockholders’ Equity
Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding
Common stock, $0.00001 par value; 100,000,000 shares authorized; 15,999,125 and 13,603,129 shares issued and outstanding, respectively	160	136
Additional paid in capital	19,456,701	16,572,622
Accumulated deficit	(13,847,112)	(8,894,889)
Total Stockholders’ Equity	5,609,749	7,677,869
Total Liabilities and Stockholders’ Equity	7,375,818	8,653,545
Nonrelated Party [Member]
Current Liabilities
Accounts payable and accrued expenses	180,000	116,745
Accrued interest payable	106,578
Related Party [Member]
Current Liabilities
Accounts payable and accrued expenses		12,500
Accrued interest payable		98,135
Notes payable to related parties		$ 685,473

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, liquidation preference per share	$ 1,000	$ 1,000
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	15,999,125	13,603,129
Common stock, shares outstanding	15,999,125	13,603,129

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Revenue
Operating expenses
Research and development, net of contract expense reimbursements	1,140,307	669,038	3,084,488	1,048,821
General and administrative	170,423	81,864	452,342	104,711
Legal and professional	288,416	70,566	1,072,728	659,958
Total operating expenses	1,599,146	821,468	4,609,558	1,813,490
Loss from operations	(1,599,146)	(821,468)	(4,609,558)	(1,813,490)
Other income (expense)
Interest income	20,765		56,720
Finance fee			(104,245)
Change in fair value of derivative liabilities	442,900	112,797	2,118,175	94,025
Gain on sale of marketable securities			1,744
Change in fair value of marketable securities	9,606		21,134
Loss on settlement of convertible debt	(43,414)		(477,221)
Gain on settlement of accounts payable		328,687		328,687
Gain on forgiveness of Paycheck Protection Program note payable				73,007
Total other income (expense)	(193,608)	(176,957)	(342,665)	(464,049)
Loss before income taxes	(1,775,254)	(998,425)	(4,952,223)	(2,277,539)
Provision for income taxes
Net loss	(1,792,754)	(998,425)	(4,952,223)	(2,277,539)
Dividend on Series A Preferred Stock		(19,473)		(71,009)
Net loss attributable to common stockholders	$ (1,792,754)	$ (1,017,898)	$ (4,952,223)	$ (2,348,548)
Weighted average common shares outstanding basic	15,744,210	10,164,979	14,554,878	9,723,510
Net loss per shares - basic	$ (0.11)	$ (0.10)	$ (0.34)	$ (0.23)
Net loss per shares - diluted	$ (0.11)	$ (0.10)	$ (0.34)	$ (0.23)
Related Party [Member]
Other income (expense)
Interest expense		$ (13,725)	$ (6,825)	$ (39,108)
Nonrelated Party [Member]
Other income (expense)
Interest expense	$ (623,465)	$ (604,716)	$ (1,952,147)	$ (920,660)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock to be Issued [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021		$ 93	$ 4,150,867	$ 16,340	$ (5,795,432)	$ (1,628,132)
Balance, shares at Dec. 31, 2021	1,213	9,312,152
Warrants issued for financing costs			319,643			319,643
Stock-based compensation			166,533			166,533
Net loss					(681,839)	(681,839)
Common stock issued for restricted stock units
Common stock issued for restricted stock units, shares		5,104
Common stock issued for conversion of accrued interest			16,340	(16,340)
Common stock issued for conversion of accrued interest, shares		839
Dividends on Series A preferred stock					(25,768)	(25,768)
Balance at Mar. 31, 2022		$ 93	4,653,383		(6,503,039)	(1,849,563)
Balance, shares at Mar. 31, 2022	1,213	9,318,095
Balance at Dec. 31, 2021		$ 93	4,150,867	16,340	(5,795,432)	(1,628,132)
Balance, shares at Dec. 31, 2021	1,213	9,312,152
Net loss						$ (2,277,539)
Common stock issued for conversion of convertible debt, shares		147,500				839
Common stock issued for cash, shares		1,409,771
Balance at Sep. 30, 2022		$ 136	16,548,719		(8,143,980)	$ 8,404,875
Balance, shares at Sep. 30, 2022		13,586,393
Balance at Mar. 31, 2022		$ 93	4,653,383		(6,503,039)	(1,849,563)
Balance, shares at Mar. 31, 2022	1,213	9,318,095
Stock-based compensation			166,533			166,533
Net loss					(597,275)	(597,275)
Common stock issued for restricted stock units
Common stock issued for restricted stock units, shares		5,104
Dividends on Series A preferred stock					(25,768)	(25,768)
Balance at Jun. 30, 2022		$ 93	4,819,916		(7,126,082)	(2,306,073)
Balance, shares at Jun. 30, 2022	1,213	9,323,199
Warrants issued for financing costs			92,598			92,598
Stock-based compensation			23,667			23,667
Net loss					(998,425)	(998,425)
Common stock issued for conversion of convertible debt		$ 1	588,523			$ 588,524
Common stock issued for conversion of convertible debt, shares		147,500				0
Common stock issued for restricted stock units
Common stock issued for restricted stock units, shares		1,045
Dividends on Series A preferred stock					(19,473)	(19,473)
Common stock issued for cash		$ 14	10,031,401			10,031,415
Common stock issued for cash, shares		1,409,771
Warrants exercised for cash		$ 14	14,084			14,098
Warrants exercised for cash, shares		1,409,771
Common stock issued for exercise of warrants with settlement of notes payable		$ 9	576,467			576,476
Common stock issued for exercise of warrants with settlement of notes payable, shares		857,780
Common shares issued for dividends on and conversion of Series A preferred stock		$ 5	402,064			402,069
Common shares issued for dividends on and conversion of Series A preferred stock, shares	(1,213)	437,327
Balance at Sep. 30, 2022		$ 136	16,548,719		(8,143,980)	8,404,875
Balance, shares at Sep. 30, 2022		13,586,393
Balance at Dec. 31, 2022		$ 136	16,572,622		(8,894,889)	7,677,869
Balance, shares at Dec. 31, 2022		13,603,129
Warrants issued for financing costs			99,543			99,543
Financing fees allocated to warrants			(8,727)			(8,727)
Common stock issued for conversion of accrued interest and principal		$ 1	104,546			104,547
Common stock issued for conversion of accrued interest and principal, shares		50,998
Stock-based compensation			8,333			8,333
Net loss					(975,097)	(975,097)
Balance at Mar. 31, 2023		$ 137	16,776,317		(9,869,986)	6,906,468
Balance, shares at Mar. 31, 2023		13,654,127
Balance at Dec. 31, 2022		$ 136	16,572,622		(8,894,889)	7,677,869
Balance, shares at Dec. 31, 2022		13,603,129
Net loss						$ (4,952,223)
Common stock issued for conversion of convertible debt, shares						2,380,996
Common stock issued for cash						$ 10,031,415
Common stock issued for cash, shares		2,380,996
Balance at Sep. 30, 2023		$ 160	19,456,701		(13,847,112)	5,609,749
Balance, shares at Sep. 30, 2023		15,999,125
Balance at Mar. 31, 2023		$ 137	16,776,317		(9,869,986)	6,906,468
Balance, shares at Mar. 31, 2023		13,654,127
Common stock issued for conversion of accrued interest and principal		$ 18	2,163,974			2,163,992
Common stock issued for conversion of accrued interest and principal, shares		1,827,911
Stock-based compensation			49,522			49,522
Net loss					(2,184,372)	(2,184,372)
Balance at Jun. 30, 2023		$ 155	18,989,813		(12,054,358)	6,935,610
Balance, shares at Jun. 30, 2023		15,482,038
Stock-based compensation			37,583			37,583
Net loss					(1,792,754)	(1,792,754)
Common stock issued for conversion of convertible debt		$ 5	429,305			$ 429,310
Common stock issued for conversion of convertible debt, shares		502,087				502,087
Common stock issued for restricted stock units
Common stock issued for restricted stock units, shares		15,000
Stock based compensation, shares
Common stock issued for cash, shares		502,087
Balance at Sep. 30, 2023		$ 160	$ 19,456,701		$ (13,847,112)	$ 5,609,749
Balance, shares at Sep. 30, 2023		15,999,125

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,952,223)	$ (2,277,539)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	4,828	4,484
Change in fair value of derivative liabilities	(2,118,175)	(94,025)
Amortization of debt discount and finance fees	1,654,724	885,505
Gain on marketable securities	(1,744)
Change in fair value of marketable securities	(21,134)
Accrued interest settled with common stock	294,927
Loss on settlement of convertible debt	477,221
Gain on settlement of accounts payable		(328,687)
Gain on forgiveness of Paycheck Protection Program note payable		(73,007)
Gain on interest relief on conversion of notes payable		12,625
Stock-based compensation	95,438	356,733
Changes in operating assets and liabilities:
Accrued interest income	(12,435)
Contracts receivable		(5,954)
Prepaid expenses	(8,956)	(158,276)
Operating lease right of use asset
Accounts payable and accrued expenses	63,255	(392,473)
Accounts payable and accrued expenses - related parties	(12,500)
Accrued interest payable	106,578	5,727
Accrued interest payable - related parties	(98,135)	38,286
Change in operating lease asset and liability	9,358	(3,986)
Net cash used in operating activities	(4,518,973)	(2,030,587)
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in marketable securities	(2,977,714)
Proceeds from disposition of marketable securities	80,000
Purchase of equipment	(19,046)
Net cash used in investing activities	(2,916,760)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares and exercise of warrants		10,045,513
Proceeds from note payable-related party		50,000
Repayment of note payable-related party	(685,473)	(50,000)
Proceeds from convertible notes payable and warrants	3,935,000	600,715
Payment for finance costs related to convertible note payable	(345,000)
Net cash provided by financing activities	2,904,527	10,646,228
Net change in cash and cash equivalents	(4,531,206)	8,615,641
Cash and cash equivalents, beginning of period	8,417,203	504,749
Cash and cash equivalents, end of period	3,885,997	9,120,390
Cash paid for:
Interest	102,373	17,489
Income taxes
Supplemental non-cash financing activities:
Common stock issued for conversion of accrued interest		16,340
Common stock issued for settlement of debt	2,697,849	588,524
Common stock issued for exercise of warrants with settlement of notes payable		576,476
Common stock issued for dividend payable		402,067
Warrants issued for financing fees	90,816
Initial recognition of right of use asset and liability	$ 365,556

Organization and Liquidity

Organization and Liquidity	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Liquidity	Note 1 – Organization and Liquidity Organization and Line of Business The Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed articles of conversion with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name to Shuttle Pharmaceuticals, Inc. (“Shuttle”). In connection with the conversion the Company issued 45,000,000 100 The Company’s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications. The Company’s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company’s Ropidoxuridine product, which is used with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (“SBIR”) contract provided by the National Cancer Institute (“NCI”), a unit of the National Institutes of Health (“NIH”). Ropidoxuridine has been further developed though the Company’s collaborations with scientists at the University of Virginia for use in combination with proton therapy to improve patient survival. Historically, and prior to the Company’s initial public offering, the Company has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation with metabolite biomarkers and develop prostate cancer cell lines in health disparities research. The production and marketing of the Company’s products and its ongoing research and development activities will be and are subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the Food and Drug Administration (“FDA”) under the Food, Drug and Cosmetic Act. There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials. The Company’s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company now or in the future. Liquidity The Company has incurred losses since inception and a net loss of $ 4,952,223 10,022,193 4,300,000 1,018,079 2.35 3,590,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and notes required by accounting principles generally accepted in the United States of America for annual financial statements. A complete discussion of the Company’s significant accounting policies is included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all of the adjustments necessary to present the financial position of the Company as of September 30, 2023 and the results of operations and cash flows for the periods presented. The accompanying condensed consolidated financial statements of the Company have not been audited by the Company’s independent registered public accounting firm, except that the year-end condensed consolidated balance sheet was derived from audited financial statements. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2023. Basis of Consolidation The unaudited condensed consolidated financial statements have been prepared on a consolidated basis with those of the Company’s wholly-owned subsidiary, Shuttle Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated. Reclassifications Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying condensed consolidated financial statements for the valuation of derivatives, share-based compensation, useful lives for depreciation and amortization of long-lived assets, and the incremental borrowing rate used on right-of-use assets. Cash and Cash Equivalents Cash and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value. As of September 30, 2023 and December 31, 2022, cash and cash equivalents consisted of the following: Schedule of Cash and Cash Equivalents September 30, December 31, 2023 2022 Cash $ 2,867,519 $ 5,411,378 Money market funds 1,018,478 3,005,825 Total cash and cash equivalents $ 3,885,997 $ 8,417,203 Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $ 250,000 3,256,000 Marketable Securities Our investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading of debt securities are charged to income. The marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding balance of $ 2,920,592 0 56,720 0 1,744 0 21,134 0 Fair Value of Financial Instruments The Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair Value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: ● Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. ● Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. ● Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires a significant judgment or estimation. Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. The carrying amounts of the Company’s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Set out below are the Company’s financial instruments that are required to be remeasured at fair value on a recurring basis and their fair value hierarchy as of September 30, 2023 (none for December 31, 2022): Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis September 30, 2023 Level 1 Level 2 Level 3 Carrying Value Assets Marketable Securities: United States Treasury Bonds $ 2,920,592 $ - $ - $ 2,920,592 Liabilities Derivative Liability - Warrants $ - $ - $ 497,157 $ 497,157 Derivative Liability - Accelerated feature - - 15,668 15,668 Total Liabilities $ - $ - $ 512,825 $ 512,825 Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For our derivative financial instruments, the Company used a Monte Carlo valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within twelve (12) months of the balance sheet date. Research and Development Expenses Research and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses, and consulting costs. In September of 2022, TCG GreenChem, Inc. (“TCG GreenChem”) was contracted for process research, development and cGMP compliant manufacture of IpdR, for which the final report was completed and delivered by TCG GreenChem during September 2023. The total project cost was $ 1,500,000 450,000 300,000 300,000 450,000 Regarding the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit companies. We understand there is more than one acceptable alternative for the accounting treatment – a reduction of costs, a deferred credit to be amortized, revenue or other income. The Company has concluded that reimbursements are more akin to a reduction of costs and applies reimbursements against incurred research costs. Net Loss Per Common Stock Net loss per share of common stock requires presentation of basic earnings per share on the face of the statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share computation. In the accompanying financial statements, basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants unless the result would be antidilutive. The dilutive effect of restricted stock units subject to vesting and other share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting shares of common stock are included in the denominator of the diluted calculation for the entire period being presented. For the three and nine months ended September 30, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share September 30, September 30, 2023 2022 Convertible notes (Note 6) 1,101,830 - Warrants 1,446,155 20,000 Restricted stock units 168,050 - 2,716,035 20,000 Recent Accounting Pronouncements The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases
Leases	Note 3 – Leases Operating lease right-of-use (“ROU”) assets and liabilities are recognized at the present value of the future lease payments as of the lease commencement date. The interest rate used to determine the present value of our lease ending in October of 2023 was our incremental borrowing rate estimated at 10% when the lease was entered into in 2019. Our new lease beginning in June of 2023, the interest rate used was an equity built up, risk adjusted rate, estimated to be 10.48%, as the interest rate implicit in most of our leases is not readily determinable. The Company currently has two lease agreements which allow for the use of a laboratory facility. The first is for a monthly payment of $ 6,480 6,480 October 31, 2023 7,206 at the rate of 3% commenced June 1, 2023 3,300 43,234 3,891 3,315 The following summarizes the right-of use asset and lease information for the Company’s operating leases: Schedule of Right-of Use Asset and Lease Information About Operating Lease 2023 2022 Nine Months Ended September 30, 2023 2022 Operating lease cost $ 83,230 $ 52,631 Sublease income (6,377 ) (4,949 ) Total lease cost $ 76,853 $ 47,682 Other information Cash paid for operating cash flows from operating leases $ 73,884 $ 56,617 Right-of-use assets obtained in exchange for new operating lease liability $ 365,556 $ - Weighted-average remaining lease term — operating leases (year) 4.93 1.05 Weighted-average discount rate — operating leases 10.48 % 10 % Future non-cancelable minimum lease payments under the operating lease liability as of September 30, 2023, are as follows: Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability Years Ended December 31, Lease Ending Lease Ending As of September 30, 2023 Years Ended December 31, Lease Ending Lease Ending 2023 (remaining three months) $ 15,677 $ 6,480 2024 91,545 - 2025 94,247 - 2026 97,074 - 2027 99,986 - 2028 68,235 - Total future minimum lease payments 466,764 6,480 Less: imputed interest (103,785 ) - Present value of payments $ 362,979 $ 6,480

Notes Payable-Related Party

Notes Payable-Related Party	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Notes Payable-Related Party	Note 4 – Notes Payable-Related Party On December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal balance of $ 426,243 7.5% December 31, 2021 139,229 7.5% December 31, 2021 In December of 2021 the maturity dates of these loans were further extended to June 30, 2022. In July of 2022, the notes were extended to June 30, 2023 On June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $ 120,000 7.5% During the six months ended June 30, 2023 principal payments of $ 685,473 102,373 0

Convertible Notes and Notes Pay

Convertible Notes and Notes Payable	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Convertible Notes and Notes Payable	Note 5 – Convertible Notes and Notes Payable Alto Opportunity Master Fund, SPC On January 11, 2023, the Company entered into a securities purchase agreement (the “SPA”) with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, a Cayman entity (the “Investor”), pursuant to which the Company sold to the Investor a $ 4,300,000 1,018,079 2.35 3,935,000 366% the Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $2.35, (ii) 90% of the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to payment date. The noteholder may convert at any time at a fixed price of $2.35 per share 1,442,000 5% In conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the “Security Agreement”), an intellectual property security agreement (the “IP Security Agreement”) and a subsidiary guaranty (the “Subsidiary Guaranty”). The security agreements and guaranty allow, among other things, for the Investor to have a security interest in and place a lien on all of the Company’s assets and intellectual property until such time as the Alto Convertible Note is paid off. In addition, the SPA called for the Company to enter into a springing deposit account control agreement (the “Springing DACA”), which, in the event the Company defaults on its repayment of the Alto Convertible Note, would allow the Investor to assume control of the Company’s bank account only with regard to any funds remaining outstanding under the Alto Convertible Note. As such, in conjunction with entry into the SPA, the Company established a separate bank account in which it deposited the Investment Amount and pursuant to which the Company, the Investor and the bank holding the Investment Amount, First Republic Bank, entered into the Springing DACA agreement. As the Investment Amount had been held at First Republic Bank, in light of certain banking crises then affecting smaller banks, on March 12, 2023, the Company and the Investor moved the Investment Amount from First Republic Bank, after which time the Springing DACA was no longer in effect. Further, pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor agreed that all of the Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing DACA would no longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $ 10 Boustead Securities, LLC (“Boustead”) served as a placement agent for the Alto Convertible Note and Warrant offering and received $ 345,000 71,266 2.35 five years 110 3.53 99,543 The Company allocated the finance costs related to the Boustead placement agent fee of $ 345,000 232,027 104,245 8,727 The Company allocated to the debt component of the note an original discount of $ 300,000 65,000 215,000 1,442,000 1,288,543 3,310,543 During the three and nine months ended September 30, 2023, the Company recorded interest expense of $ 623,465 1,952,147 538,302 1,550,479 331,800 1,925,700 54,096 294,927 502,087 2,380,996 As of September 30, 2023, the outstanding principal for the convertible note was $ 2,589,300 1,992,093 597,207

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 6 – Stockholders’ Equity Common Stock During the three and nine months ended September 30, 2023, the Company issued: ● 502,087 2,380,996 331,800 1,925,700 54,096 294,927 43,414 477,221 ● 15,000 15,000 During the three and nine months ended September 30, 2022, the Company issued: ● 0 839 0 16,340 ● 1,045 11,253 ● 1,409,771 1,409,771 10,031,415 10,031,415 ● 147,500 147,500 88,524 588,524 ● 2,267,551 2,267,551 590,574 590,574 ● 336,810 336,810 100,517 402,068 402,068 Warrants In connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase 71,266 2.35 1,018,079 2.35 A summary of activity regarding all warrants issued for the nine months ended September 30, 2023 were as follows: Schedule of Warrants Activity Number of Weighted Average Average warrants Exercise Price Life (years) Outstanding, December 31, 2022 356,810 $ 3.92 2.79 Granted - Boustead 71,266 2.35 5.00 Granted - Ayrton 1,018,079 2.35 4.00 Outstanding, September 30, 2023 1,446,155 $ 2.74 3.03 The intrinsic value of the warrants as of September 30, 2023 is $ 0 Equity Incentive Plan Our 2018 Equity Incentive Plan (the “2018 Plan”) provides for equity incentives to be granted to our employees, executive officers, directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company’s compensation committee. We have reserved 3,000,000 578,180 410,130 Restricted Stock Units We may grant restricted stock units (“RSU”) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually in one third increments from the date of appointment. During the nine months ended September 30, 2023 and 2022, pursuant to agreements with directors and officers, 159,326 0 291,400 0 95,438 356,733 As of September 30, 2023, there was $ 257,072 A summary of activity regarding the Restricted Stock Units issued follows: Schedule of Restricted Stock Units (RSUs) Number of RSU Weighted Outstanding, December 31, 2022 99,273 $ 15.06 Granted 159,326 1.83 Vested (90,549 ) - Outstanding, September 30, 2023 168,050 $ 1.98

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Derivative Liabilities	Note 7 – Derivative Liabilities Fair Value Assumptions Used in Accounting for Derivative Liabilities ASC 815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change in the fair market value as other income or expense. In January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase 1,018,079 2.35 1,189,000 The Company determined our derivative liability from the noteholder’s Acceleration Option for the Alto Convertible Note is not clearly and closely related to the host, and should be thus accounted for as a bifurcated derivative liability. We classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair value as of January 11, 2023 ($ 2,631,000 512,825 1.58 14% The key inputs for the Monte Carlo simulation for the nine months ended September 30, 2023, were as follows: Schedule of Monte Carlo Simulation Assumption Net cash settlement and down round key valuation inputs – warrants Annualized volatility 58.91 95.99 % Risk-free interest rate 4.77 5.55 VWAP 0.49 0.59 Dividend yield 0 % Exercise price 2.35 Probability of fundamental transaction 5 25 % Date of fundamental transaction 0.28 3.28 * Based on a Monte Carlo simulation analysis of 75,000 – 100,000 iterations Acceleration option key valuation inputs Annualized volatility 17.23 54.7 % Risk-free interest rate 5.16 5.55 % VWAP 0.49 0.59 Probability of fundamental transaction 5 25 % Date of fundamental transaction 0 1.45 * Based on a Monte Carlo simulation analysis of 75,000 – 100,000 iterations The following table summarizes the changes in the derivative liabilities: Schedule of Derivative Liabilities Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Warrants Accelerated Feature Balance - December 31, 2022 $ - $ - Addition of new derivatives 1,189,000 1,442,000 Gain on change in fair value (383,000 ) (858,000 ) Balance - March 31, 2023 $ 806,000 $ 584,000 Gain on change in fair value (328,243 ) (106,032 ) Balance - June 30, 2023 $ 477,757 $ 477,968 (Gain) loss on change in fair value of the derivative 19,400 (462,300 ) Balance - September 30, 2023 $ 497,157 $ 15,668 Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance - December 31, 2021 $ 94,025 Gain on change in fair value - warrants (94,025 ) Balance - September 30, 2022 $ -

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 8 – Subsequent Events Management evaluated all additional events subsequent to the balance sheet date through the date the unaudited interim condensed consolidated financial statements were issued and determined that, other than as set forth below, there were no items required to be disclosed. On October 24, 2023, the Company entered into a license agreement (the “License Agreement”) with Georgetown University (“Georgetown”), pursuant to which Georgetown agreed to license the invention known as “Predictive Biomarkers for Adverse Effects of Radiation Therapy,” (U.S. Application No. 17/476,148, titled Predictive Biomarkers for Adverse Effects of Radiation Therapy, 5

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and notes required by accounting principles generally accepted in the United States of America for annual financial statements. A complete discussion of the Company’s significant accounting policies is included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all of the adjustments necessary to present the financial position of the Company as of September 30, 2023 and the results of operations and cash flows for the periods presented. The accompanying condensed consolidated financial statements of the Company have not been audited by the Company’s independent registered public accounting firm, except that the year-end condensed consolidated balance sheet was derived from audited financial statements. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2023.
Basis of Consolidation	Basis of Consolidation The unaudited condensed consolidated financial statements have been prepared on a consolidated basis with those of the Company’s wholly-owned subsidiary, Shuttle Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying condensed consolidated financial statements for the valuation of derivatives, share-based compensation, useful lives for depreciation and amortization of long-lived assets, and the incremental borrowing rate used on right-of-use assets.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value. As of September 30, 2023 and December 31, 2022, cash and cash equivalents consisted of the following: Schedule of Cash and Cash Equivalents September 30, December 31, 2023 2022 Cash $ 2,867,519 $ 5,411,378 Money market funds 1,018,478 3,005,825 Total cash and cash equivalents $ 3,885,997 $ 8,417,203 Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $ 250,000 3,256,000
Marketable Securities	Marketable Securities Our investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading of debt securities are charged to income. The marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding balance of $ 2,920,592 0 56,720 0 1,744 0 21,134 0
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair Value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: ● Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. ● Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. ● Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires a significant judgment or estimation. Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. The carrying amounts of the Company’s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Set out below are the Company’s financial instruments that are required to be remeasured at fair value on a recurring basis and their fair value hierarchy as of September 30, 2023 (none for December 31, 2022): Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis September 30, 2023 Level 1 Level 2 Level 3 Carrying Value Assets Marketable Securities: United States Treasury Bonds $ 2,920,592 $ - $ - $ 2,920,592 Liabilities Derivative Liability - Warrants $ - $ - $ 497,157 $ 497,157 Derivative Liability - Accelerated feature - - 15,668 15,668 Total Liabilities $ - $ - $ 512,825 $ 512,825
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For our derivative financial instruments, the Company used a Monte Carlo valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within twelve (12) months of the balance sheet date.
Research and Development Expenses	Research and Development Expenses Research and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, related subcontract expenses, and consulting costs. In September of 2022, TCG GreenChem, Inc. (“TCG GreenChem”) was contracted for process research, development and cGMP compliant manufacture of IpdR, for which the final report was completed and delivered by TCG GreenChem during September 2023. The total project cost was $ 1,500,000 450,000 300,000 300,000 450,000 Regarding the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit companies. We understand there is more than one acceptable alternative for the accounting treatment – a reduction of costs, a deferred credit to be amortized, revenue or other income. The Company has concluded that reimbursements are more akin to a reduction of costs and applies reimbursements against incurred research costs.
Net Loss Per Common Stock	Net Loss Per Common Stock Net loss per share of common stock requires presentation of basic earnings per share on the face of the statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share computation. In the accompanying financial statements, basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants unless the result would be antidilutive. The dilutive effect of restricted stock units subject to vesting and other share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting shares of common stock are included in the denominator of the diluted calculation for the entire period being presented. For the three and nine months ended September 30, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share September 30, September 30, 2023 2022 Convertible notes (Note 6) 1,101,830 - Warrants 1,446,155 20,000 Restricted stock units 168,050 - 2,716,035 20,000
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	Cash and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value. As of September 30, 2023 and December 31, 2022, cash and cash equivalents consisted of the following: Schedule of Cash and Cash Equivalents September 30, December 31, 2023 2022 Cash $ 2,867,519 $ 5,411,378 Money market funds 1,018,478 3,005,825 Total cash and cash equivalents $ 3,885,997 $ 8,417,203
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Set out below are the Company’s financial instruments that are required to be remeasured at fair value on a recurring basis and their fair value hierarchy as of September 30, 2023 (none for December 31, 2022): Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis September 30, 2023 Level 1 Level 2 Level 3 Carrying Value Assets Marketable Securities: United States Treasury Bonds $ 2,920,592 $ - $ - $ 2,920,592 Liabilities Derivative Liability - Warrants $ - $ - $ 497,157 $ 497,157 Derivative Liability - Accelerated feature - - 15,668 15,668 Total Liabilities $ - $ - $ 512,825 $ 512,825
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	For the three and nine months ended September 30, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share September 30, September 30, 2023 2022 Convertible notes (Note 6) 1,101,830 - Warrants 1,446,155 20,000 Restricted stock units 168,050 - 2,716,035 20,000

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases
Schedule of Right-of Use Asset and Lease Information About Operating Lease	The following summarizes the right-of use asset and lease information for the Company’s operating leases: Schedule of Right-of Use Asset and Lease Information About Operating Lease 2023 2022 Nine Months Ended September 30, 2023 2022 Operating lease cost $ 83,230 $ 52,631 Sublease income (6,377 ) (4,949 ) Total lease cost $ 76,853 $ 47,682 Other information Cash paid for operating cash flows from operating leases $ 73,884 $ 56,617 Right-of-use assets obtained in exchange for new operating lease liability $ 365,556 $ - Weighted-average remaining lease term — operating leases (year) 4.93 1.05 Weighted-average discount rate — operating leases 10.48 % 10 %
Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability	Future non-cancelable minimum lease payments under the operating lease liability as of September 30, 2023, are as follows: Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability Years Ended December 31, Lease Ending Lease Ending As of September 30, 2023 Years Ended December 31, Lease Ending Lease Ending 2023 (remaining three months) $ 15,677 $ 6,480 2024 91,545 - 2025 94,247 - 2026 97,074 - 2027 99,986 - 2028 68,235 - Total future minimum lease payments 466,764 6,480 Less: imputed interest (103,785 ) - Present value of payments $ 362,979 $ 6,480

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Warrants Activity	A summary of activity regarding all warrants issued for the nine months ended September 30, 2023 were as follows: Schedule of Warrants Activity Number of Weighted Average Average warrants Exercise Price Life (years) Outstanding, December 31, 2022 356,810 $ 3.92 2.79 Granted - Boustead 71,266 2.35 5.00 Granted - Ayrton 1,018,079 2.35 4.00 Outstanding, September 30, 2023 1,446,155 $ 2.74 3.03
Schedule of Restricted Stock Units (RSUs)	A summary of activity regarding the Restricted Stock Units issued follows: Schedule of Restricted Stock Units (RSUs) Number of RSU Weighted Outstanding, December 31, 2022 99,273 $ 15.06 Granted 159,326 1.83 Vested (90,549 ) - Outstanding, September 30, 2023 168,050 $ 1.98

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Monte Carlo Simulation Assumption	The key inputs for the Monte Carlo simulation for the nine months ended September 30, 2023, were as follows: Schedule of Monte Carlo Simulation Assumption Net cash settlement and down round key valuation inputs – warrants Annualized volatility 58.91 95.99 % Risk-free interest rate 4.77 5.55 VWAP 0.49 0.59 Dividend yield 0 % Exercise price 2.35 Probability of fundamental transaction 5 25 % Date of fundamental transaction 0.28 3.28 * Based on a Monte Carlo simulation analysis of 75,000 – 100,000 iterations Acceleration option key valuation inputs Annualized volatility 17.23 54.7 % Risk-free interest rate 5.16 5.55 % VWAP 0.49 0.59 Probability of fundamental transaction 5 25 % Date of fundamental transaction 0 1.45 * Based on a Monte Carlo simulation analysis of 75,000 – 100,000 iterations
Schedule of Derivative Liabilities	The following table summarizes the changes in the derivative liabilities: Schedule of Derivative Liabilities Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Warrants Accelerated Feature Balance - December 31, 2022 $ - $ - Addition of new derivatives 1,189,000 1,442,000 Gain on change in fair value (383,000 ) (858,000 ) Balance - March 31, 2023 $ 806,000 $ 584,000 Gain on change in fair value (328,243 ) (106,032 ) Balance - June 30, 2023 $ 477,757 $ 477,968 (Gain) loss on change in fair value of the derivative 19,400 (462,300 ) Balance - September 30, 2023 $ 497,157 $ 15,668 Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance - December 31, 2021 $ 94,025 Gain on change in fair value - warrants (94,025 ) Balance - September 30, 2022 $ -

Organization and Liquidity (Det

Organization and Liquidity (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

Aug. 12, 2016

Jan. 31, 2023

Sep. 30, 2022

Sep. 30, 2023

Jun. 30, 2023

Mar. 31, 2023

Sep. 30, 2022

Jun. 30, 2022

Mar. 31, 2022

Sep. 30, 2023

Sep. 30, 2022

Jan. 11, 2023

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Net income loss

$ 1,792,754

$ 2,184,372

$ 975,097

$ 998,425

$ 597,275

$ 681,839

$ 4,952,223

$ 2,277,539

Proceeds from issuance or sale of equity

$ 10,022,193

Exercisable price per share

$ 2.35

Securities Purchase Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Exercisable price per share

$ 2.35

Institutional Investor [Member] | Securities Purchase Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Debt instrument, face amount

$ 4,300,000

Net proceeds from warrants

$ 3,590,000

Common Stock [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Conversion of stock, shares issued

45,000,000

Sale of stock, percentage of ownership after transaction

100%

Net income loss

Common Stock [Member] | Institutional Investor [Member] | Securities Purchase Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Four year warrant to purchase

1,018,079

Exercisable price per share

$ 2.35

Schedule of Cash and Cash Equiv

Schedule of Cash and Cash Equivalents (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash	$ 2,867,519	$ 5,411,378
Money market funds	1,018,478	3,005,825
Total cash and cash equivalents	$ 3,885,997	$ 8,417,203

Schedule of Fair Value, Assets

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)	Sep. 30, 2023 USD ($)
Liabilities
Total Liabilities	$ 512,825
Warrant [Member]
Liabilities
Derivative Liability - Accelerated feature	497,157
Accelerated Feature [Member]
Liabilities
Derivative Liability - Accelerated feature	15,668
US Treasury Securities [Member]
Assets
United States Treasury Bonds	2,920,592
Fair Value, Inputs, Level 1 [Member]
Liabilities
Total Liabilities
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Liabilities
Derivative Liability - Accelerated feature
Fair Value, Inputs, Level 1 [Member] | Accelerated Feature [Member]
Liabilities
Derivative Liability - Accelerated feature
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Assets
United States Treasury Bonds	2,920,592
Fair Value, Inputs, Level 2 [Member]
Liabilities
Total Liabilities
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Liabilities
Derivative Liability - Accelerated feature
Fair Value, Inputs, Level 2 [Member] | Accelerated Feature [Member]
Liabilities
Derivative Liability - Accelerated feature
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Assets
United States Treasury Bonds
Fair Value, Inputs, Level 3 [Member]
Liabilities
Total Liabilities	512,825
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Liabilities
Derivative Liability - Accelerated feature	497,157
Fair Value, Inputs, Level 3 [Member] | Accelerated Feature [Member]
Liabilities
Derivative Liability - Accelerated feature	15,668
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Assets
United States Treasury Bonds

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	2,716,035	20,000	2,716,035	20,000
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,101,830		1,101,830
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,446,155	20,000	1,446,155	20,000
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	168,050		168,050

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended			9 Months Ended
	Jun. 08, 2023	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash FDIC insured amount		$ 250,000			$ 250,000
Cash, uninsured amount		3,256,000			3,256,000
Marketable securitie outstanding balance		2,920,592			2,920,592
Interest income					56,720	$ 0
Marketable securities realized gain loss					1,744	0
Marketable securities unrealized gain loss					21,134	$ 0
TCG Green Chem Inc [Member]
Project expected cost		1,500,000			$ 1,500,000
Payments to invoices in research and development	$ 300,000		$ 300,000	$ 450,000
Other research and development expense		$ 450,000

Schedule of Right-of Use Asset

Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Leases
Operating lease cost	$ 83,230	$ 52,631
Sublease income	(6,377)	(4,949)
Total lease cost	76,853	47,682
Other information
Cash paid for operating cash flows from operating leases	73,884	56,617
Right-of-use assets obtained in exchange for new operating lease liability	$ 365,556
Weighted-average remaining lease term - operating leases (year)	4 years 11 months 4 days	1 year 18 days
Weighted-average discount rate - operating leases	10.48%	10%

Schedule of Future Non-cancelab

Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)	Sep. 30, 2023 USD ($)
August 31, 2028 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
2023 (remaining three months)	$ 15,677
2024	91,545
2025	94,247
2026	97,074
2027	99,986
2028	68,235
Total future minimum lease payments	466,764
Less: imputed interest	(103,785)
Present value of payments	362,979
October 31, 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
2023 (remaining three months)	6,480
2024
2025
2026
2027
2028
Total future minimum lease payments	6,480
Less: imputed interest
Present value of payments	$ 6,480

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)		9 Months Ended
	Feb. 16, 2023	Sep. 30, 2023
Lessee, Lease, Description [Line Items]
Lessee, operating lease, assumptions and judgments, discount rate, description		The interest rate used to determine the present value of our lease ending in October of 2023 was our incremental borrowing rate estimated at 10% when the lease was entered into in 2019. Our new lease beginning in June of 2023, the interest rate used was an equity built up, risk adjusted rate, estimated to be 10.48%, as the interest rate implicit in most of our leases is not readily determinable.
Lessee, operating lease, description		The first is for a monthly payment of $6,480, with a security deposit of $6,480 held for the duration of the lease, and commenced on October 1, 2018, with the first payment made on January 1, 2019
Payments for rent		$ 6,480
Deposits		$ 6,480
Lease expiration date		Oct. 31, 2023
Common area maintenance cost	$ 3,300	$ 3,315
Proceeds from lines of credit		43,234
Security deposit		$ 3,891
New Lease Agreement [Member]
Lessee, Lease, Description [Line Items]
Lessee, operating lease, description	commenced June 1, 2023
Payments for rent	$ 7,206
Rent variable rate	3%

Notes Payable-Related Party (De

Notes Payable-Related Party (Details Narrative) - USD ($)			1 Months Ended	6 Months Ended	9 Months Ended
	Jun. 21, 2021	Dec. 01, 2020	Dec. 31, 2021	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Related Party Transaction [Line Items]
Debt Instrument, Maturity Date, Description			In December of 2021 the maturity dates of these loans were further extended to June 30, 2022. In July of 2022, the notes were extended to June 30, 2023
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 102,373	$ 17,489
Debt Instrument, Increase, Accrued Interest					$ 0
Officers Spouse [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 120,000	$ 426,243
Related Party Transaction, Rate	7.50%	7.50%
Related Party Transaction, Date		Dec. 31, 2021
Proceeds from (Repayments of) Related Party Debt				$ 685,473
Interest Paid, Excluding Capitalized Interest, Operating Activities				$ 102,373
Related Party Officer [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction		$ 139,229
Related Party Transaction, Rate		7.50%
Related Party Transaction, Date		Dec. 31, 2021

Convertible Notes and Notes P_2

Convertible Notes and Notes Payable (Details Narrative)		3 Months Ended		9 Months Ended
	Jan. 11, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) shares	Jan. 31, 2023 $ / shares shares
Short-Term Debt [Line Items]
Convertible debt		$ 2,589,300		$ 2,589,300
Warrants to purchase common stock | shares						1,018,079
Warrants exerciable shares | $ / shares						$ 2.35
Proceeds from convertible note payable				3,935,000	$ 600,715
Convertible notes payable		10,000,000		10,000,000
Allocation of financing costs				345,000
Legal fees		288,416	$ 70,566	1,072,728	$ 659,958
Interest expense debt		538,302		1,550,479
Accrued interest				0
Amortization of Debt Issuance Costs				1,992,093
Convertible note payable		597,207		597,207
Common Stock [Member]
Short-Term Debt [Line Items]
Debt, principal		$ 331,800		$ 1,925,700
Stock Issued During Period, Shares, New Issues | shares		502,087	1,409,771	2,380,996	1,409,771
Measurement Input, Expected Term [Member]
Short-Term Debt [Line Items]
Expected years		5 years		5 years
Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input		110		110
Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding measurement input		3.53		3.53
Boustead Securities LLC [Member]
Short-Term Debt [Line Items]
Warrants to purchase common stock | shares		71,266		71,266
Warrants exerciable shares | $ / shares		$ 2.35		$ 2.35
Warrant derivative liability		$ 104,245		$ 104,245
Proceeds from convertible note and warrant offering				345,000
Fair value of warrants				99,543
Allocation of financing costs				232,027
Equity warrant as reduction in additional paid in capital		8,727		8,727
Interest expense debt		623,465		1,952,147
Debt, principal		331,800		1,925,700
Accrued interest		54,096		294,927
Boustead Securities LLC [Member] | Convertible Note [Member]
Short-Term Debt [Line Items]
Fair value of warrants				1,288,543
Debt discount		300,000		300,000
Legal fees				65,000
Interest fee				215,000
Debt principal amount		$ 1,442,000		1,442,000
Interest expense debt				$ 3,310,543
Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Convertible debt	$ 4,300,000
Warrants to purchase common stock | shares	1,018,079
Warrants exerciable shares | $ / shares	$ 2.35
Proceeds from convertible note payable	$ 3,935,000
Effective interest rate	366%
Debt description	the Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $2.35, (ii) 90% of the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to payment date. The noteholder may convert at any time at a fixed price of $2.35 per share
Warrant derivative liability	$ 1,442,000
Debt interest rate	5%

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants Outstanding, Beginning Balance	356,810
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 3.92
Weighted Average Life (Years), Outstanding Ending	3 years 10 days	2 years 9 months 14 days
Number of Warrants Outstanding, Ending Balance	1,446,155	356,810
Weighted Average Exercise Price, Outstanding Ending Balance	$ 2.74	$ 3.92
Boustead [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants Outstanding, Granted	71,266
Weighted Average Exercise Price, Granted	$ 2.35
Weighted Average Life (Years), Granted	5 years
Ayrton [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants Outstanding, Granted	1,018,079
Weighted Average Exercise Price, Granted	$ 2.35
Weighted Average Life (Years), Granted	4 years

Schedule of Restricted Stock Un

Schedule of Restricted Stock Units (RSUs) (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of RSUs, Outstanding, Beginning Balance | shares	99,273
Weighted Average Grant Date Fair Value Per RSU, Beginning Balance | $ / shares	$ 15.06
Number of Stock Option Outstanding, Granted | shares	159,326
Weighted Average Exercise Price, Granted | $ / shares	$ 1.83
Number of RSUs, Vested | shares	(90,549)
Weighted Average Grant Date Fair Value Per RSU, Vested | $ / shares
Number of RSUs, Outstanding, Ending Balance | shares	168,050
Weighted Average Grant Date Fair Value Per RSU, Ending Balance | $ / shares	$ 1.98

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Jan. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for conversion of convertible debt, shares	502,087	0			2,380,996	839
Accrued interest settled with common stock		$ 0				$ 16,340
Loss on settlement of convertible debt	$ 43,414				$ 477,221
Common stock vesting of restricted stock unit		1,045				11,253
Common stock issued for cash		$ 10,031,415			10,031,415
Common stock issued for conversion of convertible debt,value		$ 88,524
Common stock issued for exercise of warrants, shares		2,267,551				2,267,551
Common stock issued for exercise of warrants notes payable, value		$ 590,574				$ 590,574
Number shares issued for conversion of note, Shares		336,810				336,810
Number shares issued for conversion dividends payable, shares						100,517
Number of warrants to purchase							1,018,079
Exercise price per share							$ 2.35
Aggregate intrinsic value of warrants	0				$ 0
Number of shares vested under plan					410,130
Restricted stock award granted value
Share based compensation					$ 95,438	$ 356,733
2018 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, capital shares reserved for future issuance	3,000,000				3,000,000
Number of shares granted under plan					578,180
Alto Convertible Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants to purchase							71,266
Exercise price per share							$ 2.35
Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for conversion of convertible debt, shares	15,000				15,000
Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted under plan					159,326
Share based compensation					$ 95,438	$ 356,733
Unrecognized compensation cost	$ 257,072				$ 257,072
Restricted Stock Units (RSUs) [Member] | Directors and Officers [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Restricted stock award granted shares					159,326	0
Restricted stock award granted value					$ 291,400	$ 0
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for conversion of convertible debt, shares	502,087	147,500				147,500
Debt instrument periodic payment principal	$ 331,800				1,925,700
Accrued interest settled with common stock	54,096				294,927
Loss on settlement of convertible debt	$ 43,414				$ 477,221
Common stock issued for cash, shares	502,087	1,409,771			2,380,996	1,409,771
Common stock issued for cash		$ 14
Common stock issued for conversion of convertible debt,value						$ 588,524
Common stock issued for dividends payable		$ 402,068				$ 402,068
Restricted stock award granted shares	15,000	1,045	5,104	5,104
Restricted stock award granted value

Schedule of Monte Carlo Simulat

Schedule of Monte Carlo Simulation Assumption (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares	Jan. 11, 2023 $ / shares
Measurement Input, Price Volatility [Member] | Minimum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	17.23
Measurement Input, Price Volatility [Member] | Minimum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	58.91
Measurement Input, Price Volatility [Member] | Maximum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	54.7
Measurement Input, Price Volatility [Member] | Maximum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	95.99
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	5.16
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	4.77
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	5.55
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	5.55
Measurement Input Volume Weighted Average Price [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input		1.58
Measurement Input Volume Weighted Average Price [Member] | Minimum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	0.49
Measurement Input Volume Weighted Average Price [Member] | Minimum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	0.49
Measurement Input Volume Weighted Average Price [Member] | Maximum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	0.59
Measurement Input Volume Weighted Average Price [Member] | Maximum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	0.59
Measurement Input, Expected Dividend Rate [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	0
Measurement Input, Exercise Price [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	2.35
Measurement Input, Default Rate [Member] | Minimum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	5
Measurement Input, Default Rate [Member] | Minimum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	5
Measurement Input, Default Rate [Member] | Maximum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	25
Measurement Input, Default Rate [Member] | Maximum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	25
Measurement Input, Expected Term [Member] | Minimum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Term	0 years
Measurement Input, Expected Term [Member] | Minimum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Term	3 months 10 days
Measurement Input, Expected Term [Member] | Maximum [Member] | Equity Option [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Term	1 year 5 months 12 days
Measurement Input, Expected Term [Member] | Maximum [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Term	3 years 3 months 10 days

Schedule of Derivative Liabilit

Schedule of Derivative Liabilities (Details) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain on change in fair value of the derivative	$ 442,900			$ 112,797	$ 2,118,175	$ 94,025
Gain on change in fair value of the derivative	(442,900)			(112,797)	(2,118,175)	(94,025)
Accelerated Feature [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	477,968	$ 584,000
Addition of new derivatives recognized as debt discounts			$ 1,442,000
Gain on change in fair value of the derivative		(106,032)	(858,000)
Gain on change in fair value of the derivative	(462,300)
Ending balance	15,668	477,968	584,000		15,668
Gain on change in fair value of the derivative	462,300
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	477,757	806,000				94,025
Addition of new derivatives recognized as debt discounts			1,189,000
Gain on change in fair value of the derivative		(328,243)	(383,000)
Gain on change in fair value of the derivative	19,400					94,025
Ending balance	497,157	$ 477,757	$ 806,000		$ 497,157
Gain on change in fair value of the derivative	$ (19,400)					$ (94,025)

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative)	Sep. 30, 2023 USD ($)	Jan. 31, 2023 USD ($) $ / shares shares	Jan. 11, 2023 USD ($) $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of warrants to purchase | shares		1,018,079
Exercise price per share | $ / shares		$ 2.35
Warrants price | $		$ 1,189,000
Derivative, Fair Value, Net | $	$ 512,825		$ 2,631,000
Measurement Input Volume Weighted Average Price [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Implied share price | $ / shares			1.58
Derivative discount percentage			14%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Oct. 24, 2023
Subsequent Event [Member] | License Agreement [Member]
Subsequent Event [Line Items]
Royalty payments percentage	5%